C4 Therapeutics (CCCC) Total Debt (2020 - 2023)

C4 Therapeutics' Total Debt history runs 4 years deep, the most recent figure standing at $20.7 million for Q2 2023.

• On a quarterly basis, Total Debt rose 85.85% year-over-year to $20.7 million in Q2 2023; TTM through Jun 2023 was $20.7 million, a 85.85% increase from a year earlier, with the FY2022 full-year figure at $11.5 million, up 6.63% from the prior year.
• Total Debt rose to $20.7 million in Q2 2023 per CCCC's latest filing, from $14.0 million in the prior quarter.
• Across five years, Total Debt topped out at $20.7 million in Q2 2023 and bottomed at $9.9 million in Q3 2020.
• The 4-year median for Total Debt is $10.9 million (2021), against an average of $11.8 million.
• Across the five-year window, Total Debt gained 6.63% in 2022 and surged 85.85% in 2023, its largest moves.
• Year by year, Total Debt stood at $10.1 million in 2020, then grew by 7.12% to $10.8 million in 2021, then rose by 6.63% to $11.5 million in 2022, then soared by 80.02% to $20.7 million in 2023.
• Per Business Quant, the three latest CCCC Total Debt figures stand at $20.7 million (Q2 2023), $14.0 million (Q1 2023), and $11.5 million (Q4 2022).